Navigation Links
India's Breast Cancer Drug Market Will Almost Double by 2012
Date:12/10/2008

Indian Physicians Start to Incorporate Targeted Therapies to Achieve Better Efficacy and Toxicity Profiles Than Conventional Therapies, According to a Report From Decision Resources

WALTHAM, Mass., Dec. 10 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the Indian breast cancer drug market will almost double from $35 million in 2007 to $64 million by 2012. According to the new Emerging Markets report entitled Breast Cancer in India, this growth will be fueled by rising disease prevalence, increasing wealth and growing disease awareness.

The report finds that docetaxel (Sanofi-Aventis's Taxotere, Indian products) and epirubicin (Pfizer's Farmorubicin, Indian products) will continue to be the market leaders, but sales of trastuzumab and bevacizumab (Roche's Herceptin and Avastin), gemcitabine (Eli Lilly's Gemcite, Indian products), and capecitabine (Roche's Xeloda, Indian products) will grow rapidly during this period.

The report also finds that Indian physicians in the six surveyed regions (Delhi, Mumbai, Bangalore, Chennai, Jaipur and Lucknow) are encouraged by the success of targeted therapies in other major markets and have started to increasingly incorporate targeted therapies --- Herceptin, Avastin, GlaxoSmithKline's Tykerb --- into breast cancer treatment to achieve better efficacy and toxicity profiles than conventional therapies. However, premium prices are the major constraint for market uptake.

"India's fast-growing economy will drive demand for novel therapies with higher efficacy and fewer side effects, which usually command high prices, among the burgeoning middle class and higher-income breast cancer patients," added Jing Wu, analyst at Decision Resources.

EMERGING MARKETS REPORTS

The Ultimate Analysis of Pharmaceutical Markets in China and India

Decision Resources is the FIRST and ONLY company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Natalia Morales                          Elizabeth Marshall
    Decision Resources                       Decision Resources, Inc.
    781-296-2691                             781-296-2563
    nmorales@dresources.com                  emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Survival differences by race most apparent in advanced stages of breast cancer
2. MRI finds breast cancer before it becomes dangerous
3. Pathway links inflammation, angiogenesis and breast cancer
4. Drop in breast cancer incidence linked to hormone use, not mammograms
5. Breast cancer prevention practices vary across Canada
6. Eating junk food whilst pregnant and breastfeeding may lead to obese offspring
7. Acrylamide Wont Raise Breast Cancer Risk
8. New link between estrogen and breast cancer
9. Hypnosis Eases Pain of Breast Cancer Surgery
10. Discovery suggests location of genes for breast density, a strong risk factor for breast cancer
11. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, ... Elite. The attorneys chosen by their peers for this recognition are considered among the ... Traurig Shareholders received special honors as members of this year’s Legal Elite Hall of ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology and specialty ... Bracket eCOA (SM) 6.0, at the 52 nd ... in Philadelphia , Pennsylvania.  A demonstration of ... its kind to fully integrate with RTSM, will be held ... a flexible platform for electronic clinical outcomes assessments that is ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas ... Brasil as the company,s second affiliate in Latin America . ... ... of Astellas Farma Colombia ... ...
Breaking Medicine Technology: